长春高新注射用GenSci136临床试验申请获批

Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), received approval from the National Medical Products Administration for the clinical trial application of its injectable drug GenSci136, which is intended for the treatment of Immunoglobulin A Nephropathy (IgAN) [1] Group 1 - Jinsai Pharmaceutical's injectable GenSci136 is a self-developed Class 1 biological product [1] - The clinical trial application for GenSci136 has been approved for use in treating IgAN and generalized myasthenia gravis [1]